McKesson reports Q1 adjusted EPS $7.88, consensus $7.21

Reports Q1 revenue $79.28B, consensus $82.53B. McKesson CEO Brian Tyler said: “McKesson delivered Adjusted Earnings per Diluted Share growth of 8% in the first quarter. As a result of our first quarter performance and confidence for the remainder of the year, we are raising our guidance range for fiscal 2025 Adjusted Earnings per Diluted Share to $31.75 to $32.55. I want to thank the McKesson employees for their hard work across the enterprise in service of our customers. We continue to advance our strategic priorities leveraging our broad capabilities across the enterprise. Strong momentum continues across our U.S. Pharmaceutical segment, particularly within our broad Oncology offerings. First quarter results were impacted by lower contributions from access programs in our Prescription Technology Solutions segment, and slower growth, including customer mix and demand shifts, in our Medical-Surgical business. We remain confident in our strategy and ability to deliver on our raised fiscal 2025 guidance and longer-term objectives. We are also pleased that the Board approved a 15% increase to the dividend, marking the eighth consecutive year of a dividend increase. The Board also authorized a $4.0 billion increase to the share repurchase program. These actions reflect the strong performance and financial position of the Company, and the confidence the Board and Management have in our future growth prospects.”